Results · Apr-Jun 2026
SMS Pharmaceuticals Q1 FY27 results
Sales grew 6% to ₹207 crore from ₹196 crore in Apr-Jun 2025.
Operating profit grew 4% to ₹41 crore, an operating margin of 19.8% (down 0.3 points from a year ago).
Net profit grew 2% to ₹20.9 crore from ₹20.5 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −13%, net profit −36%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 207.0 | 196.0 | +6% |
| Operating profit (EBITDA) | 41.0 | 39.4 | +4% |
| Operating margin | 19.8% | 20.1% | −0.3 pts |
| Net profit | 20.9 | 20.5 | +2% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.